What question did this study set out to answer?

To assess whether antisense phosphorothioate oligonucleotides targeting papillomavirus E2 mRNA can inhibit viral transactivation and replication to serve as a therapy for genital warts.

February 1, 1993Antimicrobial Agents and ChemotherapyOpen Access

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts

View Full Paper

Ask AI

Bookmark

Authors

LCLex M. CowsertNational Institutes of Health MFMaureen FoxUniversity of Wisconsin–Madison GZG. ZonRoma Tre University

Discussion

Member takes

Implication

In vitro study demonstrates sequence-specific inhibition of viral transactivation by antisense oligonucleotides in papillomavirus models, highlighting ISIS 2105 as a potential genital wart therapy.

Key Points

To assess whether antisense phosphorothioate oligonucleotides targeting papillomavirus E2 mRNA can inhibit viral transactivation and replication to serve as a therapy for genital warts.
Synthesized phosphorothioate oligonucleotides complementary to distinct regions of bovine and human papillomavirus E2 mRNAs.
Evaluated oligonucleotides in in vitro cell models to measure effects on E2 transactivation, viral focus formation, and optimal sequence length.
Engineered a 20-residue oligonucleotide (ISIS 2105) directed at the translation initiation site of HPV-6 and HPV-11 E2 mRNA and tested its inhibitory activity.
BPV-targeted compounds ISIS 1751 and ISIS 1753 inhibited E2 transactivation and focus formation in a concentration-dependent, sequence-specific manner, with 20-residue lengths showing optimal activity.
Compound ISIS 1755, which targeted the transrepressor initiation region, increased E2 transactivation in a dose-dependent manner without affecting focus formation.
The engineered HPV candidate ISIS 2105 selectively inhibited E2-dependent transactivation driven by HPV-11 E2 in vitro.

Cite This Study

Cowsert et al. (1993) studied this question.

synapsesocial.com/papers/6a72c5e526a7f98052de791d https://doi.org/10.1128/aac.37.2.171

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates sequence-specific inhibition of viral transactivation by antisense oligonucleotides in papillomavirus models, highlighting ISIS 2105 as a potential genital wart therapy.

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts

Discussion

Member takes

Implication

Key Points

Cite This Study

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider